Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

secukinumab

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Patients with moderate‐to‐severe psoriasis require long‐term treatment, yet few trials compare outcomes beyond a short‐term… Expand
Review
2018
Review
2018
BACKGROUND The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document… Expand
  • figure 2
  • table 1
  • table 2
  • table 3
Highly Cited
2015
Highly Cited
2015
BACKGROUND Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing… Expand
  • table 3
  • table 4
Highly Cited
2015
Highly Cited
2015
BACKGROUND In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs and symptoms of psoriatic arthritis… Expand
  • table 1
  • table 2
  • figure 1
Highly Cited
2015
Highly Cited
2015
BACKGROUND Interleukin 17A is a proinflammatory cytokine that is implicated in the pathogenesis of psoriatic arthritis. We… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2015
Highly Cited
2015
BACKGROUND Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown superior efficacy to etanercept with… Expand
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
Highly Cited
2014
Highly Cited
2014
BACKGROUND Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
Highly Cited
2013
Highly Cited
2013
BACKGROUND Ankylosing spondylitis is a chronic immune-mediated inflammatory disease characterised by spinal inflammation… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Review
2013
Review
2013
Genetic studies and correlative expression data in diseased tissues have pointed to the role of interleukin (IL)-17 and Th17… Expand
Highly Cited
2012
Highly Cited
2012
Objective The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the… Expand